Introduction
============

Many diseases of ageing characterised by complex inheritance patterns are progressive; the individual may be asymptomatic in the early stages. One of these diseases, age-related macular degeneration (AMD), is the most common cause of visual impairment and the leading cause of blindness in the elderly population in the developed world. The prevalence of AMD increases with advancing age in all populations studied. Thus, in developed nations such as the USA, UK, Canada and Australia, with increasingly aged populations, the condition affects a progressively larger segment of the population and has become a major public health issue. Early- or late-stage AMD is present in 15 per cent of individuals over the age of 60 years \[[@B1]\]. It is estimated that there are currently 9.1 million patients in the USA with AMD, of which 1.7 million suffer with the vision-threatening late-stage complications of choroidal neovascularisation (CNV) or geographic atrophy \[[@B1]\]. Moreover, it is predicted that the number of cases of early AMD will increase to 17.8 million by 2050 and, if untreated, cases of late-stage blinding AMD will increase to 3.8 million \[[@B1]\]. It has been determined that vision loss from AMD decreases quality of life by 60 per cent, similar to the experience of dealing with a stroke that requires intensive nursing care \[[@B2]\].

The clinical presentation and natural course of AMD are highly variable. The disease may present as early as the fifth decade of life or as late as the ninth decade. The clinical symptoms of AMD range from no visual disturbances in early disease to profound loss of central vision in the advanced late stages of the disease. Some patients never progress beyond early AMD; however, in 10-15 per cent of Caucasian patients with early-stage disease, the condition progresses to an exudative neovascular (or \'wet\' form) or geographic atrophic (or \'dry\' form) AMD, which threatens vision. The phenotype is characterised by development of subretinal choroidal neovascular complexes, haemorrhage and fibrosis and is typically associated with severe central vision loss \[[@B3],[@B4]\].

AMD has been one of the success stories of the genome revolution and is probably one of the best characterised of the complex trait diseases in terms of genetic predisposition (for reviews, see Allikmets and Dean \[[@B5]\] and Swaroop *et al*. \[[@B6]\]). Besides age, genetic background is the most significant non-modifiable risk factor for all stages of AMD, while smoking is the most significant modifiable risk factor \[[@B7],[@B8]\]. Initial groundbreaking studies established that loci on chromosomes (Chr) 1 and 10 \-- in particular the complement factor H (*CFH*) and the age-related maculopathy susceptibility protein 2 (*ARMS2*)/high temperature requirement factor A1 (*HTRA1*) genes, respectively \-- are significantly associated with AMD risk and protection in populations of various ethnicities \[[@B9]-[@B19]\]. Although the specific role(s) of the Chr 10 genes in AMD pathobiology has not yet been elucidated, the role of the alternative complement pathway, where *CFH*functions as a major fluid-phase regulator, is well established (see Anderson *et al*. \[[@B20],[@B21]\] Gehrs *et al*. \[[@B22],[@B23]\] Hageman *et al*. \[[@B24],[@B25]\] and Mullins *et al*. \[[@B26]\] for overviews). Early pathobiological investigations showed dysregulation of the complement cascade to be a critical early predisposing step in the development of AMD. This spurred the discovery of the association of *CFH*variants with AMD risk. Subsequent genetic investigations revealed additional associations between AMD and risk/protective variants in various complement pathway-associated genes, including complement component 2 (*C2*), complement factor B (*CFB*), complement component 3 (*C3*), complement factor H-related 1 and 3 (*CFHR1*and *CFHR3*) and complement factor I (*CFI*) \[[@B21],[@B27]-[@B38]\]. Using a genome-wide association approach, a handful of additional AMD-associated loci have been reported recently; these appear to be modestly associated with AMD risk and will probably require replication in additional cohorts to establish their role in AMD pathogenesis \[[@B39],[@B40]\] (see also Gehrs *et al*. \[[@B23]\] for a review).

A prerequisite for a new era in genetic testing and diagnosis for AMD is a robust test that accurately captures the impact of consistently replicated AMD risk variants in predicting the risk of developing CNV. Patients with CNV represent an important segment of the AMD population that would benefit from early diagnosis, given the current availability of an effective therapeutic intervention. Jakobsdottir and coworkers \[[@B41]\] recently concluded that the diagnostic value of three variants in the *CFH*, *ARMS2/HTRA1*and *C2*genes was not sufficient to discriminate between individuals with and without AMD because of the relatively low sensitivity and specificity of the combined test panel, in combination with the relatively low prevalence of late-stage disease in the general population. They applied a three single nucleotide polymorphism (SNP) test to their cohort of 640 late-stage AMD cases and 142 controls to demonstrate a clinical sensitivity of 74 per cent and a specificity of 69 per cent, with a reported area under the curve (AUC) \-- a measure of how well a test or classifier can distinguish between cases and controls \-- of 0.79. Perfect test discrimination would yield an AUC of 1.0. Jakobsdottir and colleagues also reported that the positive predictive value (PPV) of the same test is affected by different values of disease prevalence reflective of age. Seddon and colleagues \[[@B42]\] evaluated six AMD risk-associated variants in *CFH, ARMS2/HTRA1, C2, CFB*and *C3*with the goal of developing a predictive risk test for late-stage AMD. After controlling for smoking, body mass index (BMI) and vitamin intake, they demonstrated a strong association between these six risk variants and the prevalence of late-stage AMD, as well as progression to late-stage disease in early AMD patients. The progression test described by Seddon *et al*.,\[[@B42]\] which included genetic, environmental and treatment variables, achieved a performance of 83 per cent sensitivity and 68 per cent specificity, with a reported AUC of 0.82. McKay and co-workers \[[@B43]\] extended this test further, proposing a ten-SNP panel plus smoking history to predict the risk of late-stage AMD. Their inclusion of six CFH SNPs was designed to capture the haplotype structure of the locus, to improve classification performance. Zanke and colleagues \[[@B44]\] have presented risk scores by selecting marker-specific odds ratios from disparate sources and multiplying them together. As the latter approach does not benefit from a joint assessment of the markers (as they perform in combination), it may overestimate an individual\'s risk of disease.

In this study, we assessed the accuracy of a panel of 13 SNPs without consideration of environmental risk factors such as smoking or BMI, to predict the risk of developing CNV in Caucasian individuals 60 years of age and older. Test model development and validation were designed to evaluate these variants in eight AMD-associated genes (*CFH*, complement factor H-related 4 (*CFHR4*), complement factor H-related 5 (*CFHR5*) and coagulation factor XIII B subunit (*F13B*) located within the regulators of complement activation (RCA) region on Chr 1, *C2*and *CFB*on Chr 6, *C3*on Chr 19 and *ARMS2*on Chr 10. The panel of 13 SNPs was tested in well-established case-control and sibling pair cohorts from five academic centres (University of Iowa, University of Utah, Columbia University, Harvard University and Melbourne University) to validate the accuracy of the predictive test and to estimate an individual\'s genetic risk for developing late-stage CNV. Most of the disease-associated genetic variants in *CFH*, *ARMS2*, *C2*, *CFB*and *C3*were selected based on prior replication in multiple studies and performance in resolving the most frequent CFH haplotype combinations. Additional SNPs detecting variants in *CFHR4*(rs1409153), *CFHR5*(rs10922153 and rs1750311) and *F13B*(rs698859 and rs2990510) tagged novel extended haplotypes spanning the *CFH*-to-*F13B*region and were included to maximise the resolution of clinically relevant subtypes suspected to have high association with disease \[[@B45]\]. The additional SNPs were selected to distinguish the novel haplotypes from the more prevalent haplotypes reported previously (H1, H2, H3, H4) \[[@B13]\]. The performance metrics obtained during the clinical validation of the 13-SNP panel were used as a benchmark to compare with other published AMD-predictive tests directed at estimating an individual\'s risk of developing late-stage disease. Since the inclusion of several established non-genetic factors (eg smoking) was highly variable across the published tests, the focus of this investigation was to isolate the contribution conferred by genetic variation alone, in order to determine whether the more comprehensive collection of SNPs could further improve prediction accuracy. The methodology used in the clinical validation of the 13-SNP test panel was subsequently applied to two panels of markers \[[@B32],[@B42]\] that had been assessed previously and contained variants that overlapped with the markers contained within our 13 SNP panel. Both test panels were evaluated in the large collective cohort by using a validation step absent in prior publications. Testing the two panels in a large collection of subjects from different centres assembled from several independent collections was designed to minimise the introduction of selection bias inherent in a single cohort study. Additionally, the use of an independent validation sample was intended to aggressively challenge the 13-SNP panel, to anticipate performance metrics in a broader clinical setting more accurately. Running the three test panels (three SNPs, six SNPs and 13 SNPs) on the same samples allowed for the comparison of performance metrics based exclusively on genetic variants.

Materials and methods
=====================

Subjects
--------

Four well-characterised cohorts (Iowa,\[[@B13],[@B30]\] Boston,\[[@B38]\] Columbia,\[[@B13],[@B30]\] and Melbourne \[[@B46],[@B47]\]) and one recently acquired, but as yet unreported, cohort (Utah), together comprised 1,709 patients diagnosed with CNV and 1,473 disease-free controls (for which genotyping data were already available), were assessed (Table [1](#T1){ref-type="table"}). All individuals were of white European ancestry, 60 years of age and older and matched for age. All patients had given their consent and were enrolled under Institutional Review Board-approved protocols. The methods used in this study conformed to the tenets of the Declaration of Helsinki (2000) of the World Medical Association. Study subjects were examined and photographed by trained ophthalmologists; fundus photographs were graded according to published standardised classification systems. The worst affected eye of each case was used for classification purposes. All cohorts were case-controlled, with the exception of the Boston sib-pair cohort. Index patients in the Boston cohort aged 60 years or older were included in the analyses and had CNV, (as defined by subretinal haemorrhage, fibrosis or fluorescein angiographic presence of neovascularisation documented at the time of, or prior to, enrolment in the study) in at least one eye. The unaffected siblings had normal maculae at an age older than that at which the index patient was first diagnosed with CNV, as previously described \[[@B38]\]. The Utah case-control cohort was recently ascertained at the John A. Moran Eye Center, University of Utah, in Salt Lake City, Utah, USA, in a fashion identical to that of the Iowa cohort.

###### 

Number of cases (CNV disease) and controls in individual cohorts

  Cohort      Control     CNV
  ----------- ----------- -----------
  Boston      198         338
  Columbia    368         522
  Iowa        365         284
  Melbourne   441         472
  Utah        101         93
  **Total**   **1,473**   **1,709**

CNV, choroidal neovascular

Markers
-------

Thirteen SNPs, spanning four physically separate genomic loci, were genotyped in all five cohorts (Table [2](#T2){ref-type="table"}). One locus spans the *CFH*, *CFHR4, CFHR5*and *F13B*genes and comprises nine SNPs; the second consists of two SNPs, one each in *C2*and *CFB*; the third consists of a single SNP in *C3*; and the fourth consists of a single SNP in *ARMS2*. One of the CFH SNPs (rs12144939) included in the panel tags the CFHR3/1 deletion. The 13 SNPs were selected on the basis of the following characteristics: prior published replication, magnitude of estimated effect size and power to resolve clinically relevant haplotypes (CFH) \[[@B5]-[@B19]\].

###### 

Single nucleotide polymorphisms employed in first stage

  -------------------------------------------------------------------------------------------------------------
  **Marker**\[[@B48]\]   Chromosome   **Base-pair**\[[@B49]\]\   **Base-pair**\[[@B49]\]\   Gene
                                      (Build 36.3)               (Build 37.1)               
  ---------------------- ------------ -------------------------- -------------------------- -------------------
  rs1061170              1            194,925,860                196,659,237                *CFH*(exon 9)

  rs2274700              1            194,949,570                196,682,947                *CFH*(exon 10)

  rs403846               1            194,963,360                196,696,737                *CFH*(intron 14)

  rs12144939             1            194,965,568                196,698,945                *CFH*(intron 15)

  rs1409153              1            195,146,628                196,880,005                *CFHR4*

  rs1750311              1            195,220,848                196,954,225                *CFHR5*

  rs10922153             1            195,245,238                196,978,615                *CFHR5*

  rs698859               1            195,274,988                197,008,365                *F13B*

  rs2990510              1            195,287,281                197,020,658                *F13B*

  rs9332739              6            32,011,783                 31,903,804                 *C2*

  rs641153               6            32,022,159                 31,914,180                 *CFB*

  rs10490924             10           124,204,438                124,214,448                *LOC387155/ARMS2*

  rs2230199              19           6,669,387                  6,718,387                  *C3*
  -------------------------------------------------------------------------------------------------------------

Statistical methods
-------------------

Previous analyses of each cohort involved standard quality checks and exclusions. Prior to analysis, the consistency of the assignment of the DNA strand used to detect the SNPs was assessed for all available datasets and any inconsistencies resolved. The percentage of missing data and the genotype frequencies were calculated and tabulated for each SNP, both by study (data not shown) and overall (Table [3](#T3){ref-type="table"}). No SNPs showed significant deviation from Hardy-Weinberg equilibrium in the control population (*P*\> 0.05).

###### 

Homogeneity of variance

               Counts (row frequency)                              
  ------------ ---------------------------- ----------- ---------- -----------
  Boston       101                          71          26         198
               51.01%                       35.86%      13.13%     100.00%
  Columbia     218                          136         14         368
               59.24%                       36.96%      3.80%      100.00%
  Iowa         230                          117         13         360
               63.89%                       32.50%      3.61%      100.00%
  Melbourne    277                          145         16         438
               63.24%                       33.11%      3.65%      100.00%
  Utah         62                           39          0          101
               61.39%                       38.61%      0.00%      100.00%
  **Total**    **888**                      **508**     **69**     **1,465**
                                                                   
               **Counts (row frequency)**                          
  **Cohort**   **rs403846 Code = CNTL**     **Total**              
               ***AA***                     ***AG***    ***GG***   
                                                                   
  Boston       41                           102         55         198
               20.71%                       51.52%      27.78%     100.00%
  Columbia     32                           164         165        361
               8.86%                        45.43%      45.71%     100.00%
  Iowa         68                           179         118        365
               18.63%                       49.04%      32.33%     100.00%
  Melbourne    71                           229         137        437
               16.25%                       52.40%      31.35%     100.00%
  Utah         13                           61          27         101
               12.87%                       60.40%      26.73%     100.00%
  **Total**    **225**                      **735**     **502**    **1,462**
                                                                   
               **Counts (row frequency)**                          
  **Cohort**   **rs1409153 Code = CNTL**    **Total**              
               ***AA***                     ***AG***    ***GG***   
                                                                   
  Boston       67                           97          34         198
               33.84%                       48.99%      17.17%     100.00%
  Columbia     177                          161         29         367
               48.23%                       43.87%      7.90%      100.00%
  Iowa         128                          177         60         365
               35.07%                       48.49%      16.44%     100.00%
  Melbourne    150                          226         63         439
               34.17%                       51.48%      14.35%     100.00%
  Utah         31                           60          10         101
               30.69%                       59.41%      9.90%      100.00%
  **Total**    **553**                      **721**     **196**    **1,470**
                                                                   
               **Counts (row frequency)**                          
  **Cohort**   **rs10922153 Code = CNTL**   **Total**              
               ***GG***                     ***GT***    ***TT***   
                                                                   
  Boston       53                           102         43         198
               26.77%                       51.52%      21.72%     100.00%
  Columbia     55                           181         122        358
               15.36%                       50.56%      34.08%     100.00%
  Iowa         99                           172         94         365
               27.12%                       47.12%      25.75%     100.00%
  Melbourne    94                           234         113        441
               21.32%                       53.06%      25.62%     100.00%
  Utah         20                           59          21         100
               20.00%                       59.00%      21.00%     100.00%
  **Total**    **321**                      **748**     **393**    **1,462**
                                                                   
               **Counts (row frequency)**                          
  **Cohort**   **rs403846 Code = CNV**      **Total**              
               ***AA***                     ***AG***    ***GG***   
                                                                   
  Boston       141                          149         48         338
               41.72%                       44.08%      14.20%     100.00%
  Columbia     148                          255         116        519
               28.52%                       49.13%      22.35%     100.00%
  Iowa         110                          137         37         284
               38.73%                       48.24%      13.03%     100.00%
  Melbourne    179                          218         74         471
               38.00%                       46.28%      15.71%     100.00%
  Utah         33                           46          14         93
               35.48%                       49.46%      15.05%     100.00%
  **Total**    **611**                      **805**     **289**    **1,705**
                                                                   
               **Counts (row frequency)**                          
  **Cohort**   **rs698859 Code = CNV**      **Total**              
               ***AA***                     ***AG***    ***GG***   
                                                                   
  Boston       85                           147         105        337
               25.22%                       43.62%      31.16%     100.00%
  Columbia     78                           238         205        521
               14.97%                       45.68%      39.35%     100.00%
  Iowa         69                           136         79         284
               24.30%                       47.89%      27.82%     100.00%
  Melbourne    76                           233         163        472
               16.10%                       49.36%      34.53%     100.00%
  Utah         19                           49          25         93
               20.43%                       52.69%      26.88%     100.00%
  **Total**    **327**                      **803**     **577**    **1,707**

In order to determine the appropriateness of pooling the available cohorts, a chi-squared test of homogeneity of allele frequency was applied to compare frequencies across cohorts. Cohorts or subcohorts found to be a source of a departure from homogeneity of allele frequency (chi square *P*\< 0.001) were excluded from the main analysis.

Individuals with CNV were compared with the control group of subjects with no recorded disease. Genotypic multivariate and univariate unconditional logistic regression analyses were performed to evaluate the relationships between risk of CNV and the additively coded genotypes (Supplementary Analysis 1). Odds ratios (ORs) and 95 per cent confidence intervals (CIs) were calculated. The full 13-SNP panel was evaluated both with and without demographic factors of age and sex. Backward elimination was performed on the training set using a threshold of *P*\< 0.05.

Two published test models containing, respectively, three and six SNPs, and a nine-SNP model generated from backward elimination, were compared with the 13-SNP panel in terms of AUC in training and independent validation. In the event that an SNP was not present in the 13-SNP panel, a SNP with demonstrated linkage disequilibrium was used as a surrogate.

Training of classifiers was performed using 500 cases and 500 controls balanced by age and sex and randomly selected from the whole cohort. The remaining 322 controls and 632 cases were used for validation. In both analyses, ten-fold cross-validation was applied \[[@B50]\]. The predicted probability of affliction for each subject was calculated by applying the inverse-logit function; sensitivity, specificity and AUC were derived to assess classification performance.

A risk score for CNV was calculated as follows: $Sj = \textsf{intercept}\; + \;\sum_{i = 1}^{13}\beta i*Xi$ where *Sj*is the risk score for subject *j*and *βi*is the adjusted log-odds ratio for *Xi*, the additively coded genotype at marker *i*. The probability of risk for subject *j*was calculated as *pj*= exp(*Sj*)/\[1 +exp(*Sj*)\].

The optimal classification threshold was determined on the basis of accuracy, defined as the proportion of correct predictions observed in cases and controls. Different levels of prevalence, reflecting age-specific differences, were considered. The accuracy in the validation set was determined, and positive and negative predictive values were calculated. Calibration was assessed graphically as histograms showing disease incidence at different levels of predicted risk for controls and cases.

The area under the receiver operating characteristic (ROC) curve and CIs were estimated using SAS Macro %ROC \[[@B51]\]. In addition, c-statistics and CIs were calculated for the training, tenfold cross-validation and validation datasets \[[@B52],[@B53]\].

All analyses were conducted using SAS 9.1 \[[@B52]\].

Results
=======

The average ages (± standard deviation \[SD\]) of cases and controls among all cohorts were 76.4 (± 7.3) and 76.5 (± 7.1) years, respectively, and the differences were not significant (*p*= 0.86). Age matching was applied during cohort ascertainment. The chi-square test was used to assess homogeneity of allele frequency across cohorts. Frequencies of markers rs10490924, rs403846, rs1409153, rs698859, rs403846 and rs10922153 were significantly different (*P*\< 0.001) across cohorts. The frequencies of four markers \-- rs10490924, (ARMS2) rs403846, (CFH) rs1409153 (CFHR4) and rs10922153 (CFHR5) \-- in the control population and two markers \-- rs698859 (F13B) and rs403846 (CFH) \-- in the CNV population were unbalanced (Table [3](#T3){ref-type="table"}). Removal of the Columbia University cohort eliminated four of the five deviations, leaving only one SNP (rs10490924) outstanding in the Boston control population. The Boston controls and Columbia cases and controls were excluded from the main analyses based on these observations. The remaining study population contained 1,132 CNV cases and 822 controls. For the purposes of the current analysis, investigations into the differences were not pursued but could be evaluated in the future by performing structure analysis to identify potential causes for the observed differences.

Table [4](#T4){ref-type="table"} shows unadjusted association test results between the demographic and genetic factors and the risk of CNV. All factors except age were associated with risk of CNV. The c-statistic column shows the ability of a genetic factor to predict CNV risk. SNPs rs10490924, rs1061170, rs403846 and rs2274700 had c-statistics ≥0.65.

###### 

Univariate association between demographic, genetic factors and risk of choroidal neovascular (CNV) disease

  -----------------------------------------------------------------------------------------------------
                         Control\      CNV\           Odds\                  *P*-value\   c-statistic
                         (822)         (1132)         (95% CI)               (Type 3)     
  ------------ --------- ------------- -------------- ---------------------- ------------ -------------
  Age (± SD)             76.4 (7.3)    76.5 (7.1)     1.001 (0.989-1.013)    0.87         0.50

  Sex          F         451 (55%)     696 (61%)      1.313 (1.094-1.576)    0.0034       0.53

               M         371 (45%)     436 (39%)                                          

  rs10490924   *GG*      520 (63.3%)   340 (30%)      0.061 (0.04-0.093)     \< 0.0001    0.70

               *GT*      269 (32.7%)   505 (44.6%)    0.175 (0.114-0.268)                 

               *TT*      26 (3.2%)     279 (24.6%)                                        

               (blank)   7 (0.9%)      8 (0.7%)                                           

  rs1061170    *CC*      114 (13.9%)   394 (34.8%)    5.184 (3.934-6.831)    \< 0.0001    0.65

               *CT*      408 (49.6%)   535 (47.3%)    1.967 (1.575-2.456)                 

               *TT*      294 (35.8%)   196 (17.3%)                                        

               (blank)   6 (0.7%)      7 (0.6%)                                           

  rs10922153   *GG*      189 (23%)     498 (44%)      4.819 (3.64-6.382)     \< 0.0001    0.64

               *GT*      418 (50.9%)   515 (45.5%)    2.254 (1.738-2.922)                 

               *TT*      214 (26%)     117 (10.3%)                                        

               (blank)   1 (0.1%)      2 (0.2%)                                           

  rs12144939   *GG*      504 (61.3%)   930 (82.2%)    7.996 (3.842-16.639)   \< 0.0001    0.61

               *GT*      275 (33.5%)   192 (17%)      3.025 (1.432-6.391)                 

               *TT*      39 (4.7%)     9 (0.8%)                                           

               (blank)   4 (0.5%)      1 (0.1%)                                           

  rs1409153    *AA*      282 (34.3%)   192 (17%)      0.203 (0.154-0.267)    \< 0.0001    0.64

               *AG*      420 (51.1%)   539 (47.6%)    0.382 (0.3-0.487)                   

               *GG*      118 (14.4%)   396 (35%)                                          

               (blank)   2 (0.2%)      5 (0.4%)                                           

  rs1750311    *AA*      95 (11.6%)    53 (4.7%)      0.289 (0.202-0.415)    \< 0.0001    0.59

               *AC*      373 (45.4%)   411 (36.3%)    0.572 (0.472-0.692)                 

               *CC*      346 (42.1%)   667 (58.9%)                                        

               (blank)   8 (1%)        1 (0.1%)                                           

  rs2230199    *CC*      521 (63.4%)   621 (54.9%)    0.447 (0.289-0.691)    \< 0.0001    0.55

               *CG*      267 (32.5%)   428 (37.8%)    0.601 (0.385-0.94)                  

               *GG*      30 (3.6%)     80 (7.1%)                                          

               (blank)   4 (0.5%)      3 (0.3%)                                           

  rs2274700    *AA*      144 (17.5%)   48 (4.2%)      0.128 (0.09-0.183)     \< 0.0001    0.66

               *AG*      403 (49%)     378 (33.4%)    0.361 (0.296-0.441)                 

               *GG*      268 (32.6%)   696 (61.5%)                                        

               (blank)   7 (0.9%)      10 (0.9%)                                          

  rs2990510    *GG*      78 (9.5%)     183 (16.2%)    2.082 (1.541-2.813)    \< 0.0001    0.55

               *GT*      389 (47.3%)   544 (48.1%)    1.241 (1.023-1.506)                 

               *TT*      355 (43.2%)   400 (35.3%)                                        

               (blank)   (0%)          5 (0.4%)                                           

  rs403846     *AA*      137 (16.7%)   445 (39.3%)    5.059 (3.848-6.652)    \< 0.0001    0.65

               *AG*      424 (51.6%)   521 (46%)      1.914 (1.515-2.418)                 

               *GG*      257 (31.3%)   165 (14.6%)                                        

               (blank)   4 (0.5%)      1 (0.1%)                                           

  rs641153     *CC*      644 (78.3%)   984 (86.9%)    2.674 (1.115-6.41)     \< 0.0001    0.55

               *CT*      159 (19.3%)   129 (11.4%)    1.42 (0.578-3.489)                  

               *TT*      14 (1.7%)     8 (0.7%)                                           

               (blank)   5 (0.6%)      11 (1%)                                            

  rs698859     *AA*      120 (14.6%)   235 (20.8%)    1.644 (1.257-2.15)     0.0012       0.54

               *AG*      403 (49%)     541 (47.8%)    1.127 (0.922-1.378)                 

               *GG*      298 (36.3%)   355 (31.4%)                                        

               (blank)   1 (0.1%)      1 (0.1%)                                           

  rs9332739    *CC*      2 (0.2%)      1 (0.1%)       0.348 (0.032-3.85)     0.0022       0.52

               *CG*      72 (8.8%)     55 (4.9%)      0.532 (0.37-0.766)                  

               *GG*      745 (90.6%)   1069 (94.4%)                                       

               (blank)   3 (0.4%)      7 (0.6%)                                           
  -----------------------------------------------------------------------------------------------------

CI, confidence interval

Table [5](#T5){ref-type="table"} displays multivariate adjusted ORs that were significantly associated with the risk of CNV, using the additive genotype model applied to the 13-SNP panel. The ARMS2 variant rs10490924 was positively associated with risk of CNV (OR 4.279, 95 per cent CI 3.346-5.472, *p*\< 0.0001).

###### 

Calculation of choroidal neovascular disease risk score: $S = \textsf{intercept}\; + \;\sum_{i = 1}^{13}\beta i*Xi$, where *β*and *X*are as follows

  ------------------------------------------------------------------------------------------------------------------------
  Parameter    Regression\   *p*-value   *X*                           Point\     95% Wald\     Pr^a^\> Chisq   
               coefficient                                             estimate   confidence\                   
                                                                                  limits                        
  ------------ ------------- ----------- ----------------------------- ---------- ------------- --------------- ----------
  Intercept    0.7851        0.1885      1                             \--        \--           \--             \--

  rs10490924   1.4537        \<0.0001    *GG*= *0, GT*= *1, TT*= *2*   4.279      3.346         5.472           \<0.0001

  rs1061170    -0.7687       0.0105      *CT*= *1, CC*= *0, TT*= *2*   0.464      0.257         0.835           0.0105

  rs10922153   -0.6018       0.1129      *GT*= *1, GG*= *0, TT*= *2*   0.548      0.26          1.153           0.1129

  rs12144939   -0.1974       0.4375      *GG*= *0, GT*= *1, TT*= *2*   0.821      0.499         1.351           0.4375

  rs1409153    -0.1595       0.5665      *AG*= *1, GG*= *0, AA*= *2*   0.853      0.494         1.471           0.5665

  rs1750311    -0.1316       0.6834      *CC*= *0, AC*= *1, AA*= *2*   0.877      0.466         1.65            0.6834

  rs2230199    0.428         0.0009      *CC*= *0, CG*= *1, GG*= *2*   1.534      1.192         1.975           0.0009

  rs2274700    -0.7954       0.0002      *GG*= *0, AG*= *1, AA*= *2*   0.451      0.296         0.689           0.0002

  rs2990510    -0.4596       0.1358      *GT*= *1, TT*= *0, GG*= *2*   0.632      0.345         1.155           0.1358

  rs403846     0.8131        0.0404      *AG*= *1, AA*= *0, GG*= *2*   2.255      1.036         4.906           0.0404

  rs641153     -0.8243       \<0.0001    *CC*= *0, CT*= *1, TT*= *2*   0.439      0.295         0.651           \<0.0001

  rs698859     -0.015        0.9559      *AG*= *1, GG*= *0, AA*= *2*   0.985      0.58          1.673           0.9559

  rs9332739    -0.9544       0.0027      *GG*= *0, CG*= *1, CC*= *2*   0.385      0.206         0.719           0.0027
  ------------------------------------------------------------------------------------------------------------------------

^a^The probability of risk = exp(risk score)/\[1 +exp(risk score)\]

The performance of the 13-SNP panel to predict CNV relative to the control population was evaluated using tenfold cross-validation and an independent dataset. Independent datasets were scored using model parameters displayed in Table [5](#T5){ref-type="table"}. Table [6](#T6){ref-type="table"} shows the AUC evaluated for training (AUC 0.82 \[0.79-0.85\]), tenfold cross-validation (AUC 0.81 \[0.79-0.84\]) and validation (AUC 0.79 \[0.77-0.83\]). The c-statistics results were identical to AUC. These data show that the difference in performance of the training and validation sets was not significant (*P*\< 0.05). There were no significant differences between the AUC curves for the training and validation datasets with demographic factors (age, sex) added into the test model (Table [7](#T7){ref-type="table"}), presumably due to the balanced study design.

###### 

Area under the curve for training, tenfold cross-validation and independent validation on 13-SNP model

  ----------------------------------------------------------------
  Stage        Control/\   ROC\   Standard\   Confidence\   
               CNV         area   error       limits        
  ------------ ----------- ------ ----------- ------------- ------
  Training     467/482     0.82   0.01        0.79          0.85

  Tenfold\     467/482     0.81   0.01        0.79          0.84
  cross-\                                                   
  validation                                                

  Validation   322/632     0.80   0.02        0.77          0.83
  ----------------------------------------------------------------

SNP, single nucleotide polymorphism; CNV, choroidal neovascular; ROC, receiver operating characteristic

###### 

Comparison of 13-SNP model with and without demographic factors

  ----------------------------------------------------------------
  Step         Model              ROC\   Standard\   Confidence\
                                  area   error       limits
  ------------ ------------------ ------ ----------- -------------
  Training     Age +Sex +13 SNP   0.82   0.01        0.79-0.85

  Training     13 SNP             0.82   0.01        0.79-0.85

  Validation   Age +Sex +13 SNP   0.80   0.02        0.77-0.83

  Validation   13 SNP             0.80   0.02        0.77-0.83
  ----------------------------------------------------------------

There is no significant difference between the two models

ROC, receiver operating characteristic; SNP, single nucleotide polymorphism

The sensitivity and specificity of predictions were calculated in an independent dataset using the test panels in Table [5](#T5){ref-type="table"}. The ROC curve is shown in Figure [1](#F1){ref-type="fig"}. The probability of the risk of CNV was plotted as histograms for controls and cases in the independent dataset in Figure [2](#F2){ref-type="fig"}. It shows good separation between the two groups, with cases having a substantially higher probability of CNV, although some overlap is present.

![**ROC curve for validation**. ROC, receiver operating characteristic.](1479-7364-5-5-420-1){#F1}

![**Probability of choroidal neovascular (CNV) disease, calculated for validation dataset using model described in Table 2**. Red bars represent controls and blue bars represent patients with CNV disease.](1479-7364-5-5-420-2){#F2}

Accuracy, specificity, sensitivity, PPV and negative predicted values (NPV) are shown in Table [8](#T8){ref-type="table"} as a function of probability cut-off and three prevalence values. A cut-off of 0.4 corresponds to the highest accuracy (0.73), with a sensitivity of 0.82 and a specificity of 0.63. The PPV for 5.5 per cent, 10 per cent and 15 per cent prevalence values were 0.11, 0.20 and 0.28, respectively. The NPVs were all above 0.95.

###### 

Classification table

  ----------------------------------------------------------------------------------------------
  **Prob**.\   Sensitivity   Specificity   PPV %\   NPV %\   PPV %\   NPV %\   PPV %\   NPV %\
  level                                    (5.5%)   (5.5%)   (10%)    (10%)    (15%)    (15%)
  ------------ ------------- ------------- -------- -------- -------- -------- -------- --------
  0.00         100.0         0.0           5.5      \--      10.0     \--      15.0     \--

  0.02         99.8          0.2           5.5      94.5     10.0     90.0     15.0     85.0

  0.04         99.8          2.1           5.6      99.4     10.2     99.0     15.2     98.3

  0.06         99.8          4.3           5.7      99.7     10.4     99.5     15.5     99.2

  0.08         98.8          8.6           5.9      99.2     10.7     98.5     16.0     97.6

  0.10         98.1          12.0          6.1      99.1     11.0     98.3     16.4     97.3

  0.12         97.7          15.0          6.3      99.1     11.3     98.3     16.9     97.4

  0.14         97.3          18.2          6.5      99.1     11.7     98.4     17.3     97.4

  0.16         96.7          20.8          6.6      99.1     11.9     98.3     17.7     97.3

  0.18         95.9          23.8          6.8      99.0     12.3     98.1     18.2     97.0

  0.20         95.0          29.1          7.2      99.0     13.0     98.1     19.1     97.1

  0.22         93.6          33.0          7.5      98.9     13.4     97.9     19.8     96.7

  0.24         92.9          38.1          8.0      98.9     14.3     98.0     20.9     96.8

  0.26         91.7          43.3          8.6      98.9     15.2     97.9     22.2     96.7

  0.28         90.5          45.2          8.8      98.8     15.5     97.7     22.6     96.4

  0.30         88.8          48.8          9.2      98.7     16.2     97.5     23.4     96.1

  0.32         86.9          50.7          9.3      98.5     16.4     97.2     23.7     95.6

  0.34         86.1          53.7          9.8      98.5     17.1     97.2     24.7     95.6

  0.36         85.5          56.7          10.3     98.5     18.0     97.2     25.8     95.7

  0.38         83.4          60.4          10.9     98.4     19.0     97.0     27.1     95.4

  0.40         81.7          63.2          11.4     98.3     19.8     96.9     28.1     95.1

  0.42         80.5          65.3          11.9     98.3     20.5     96.8     29.0     95.0

  0.44         78.4          66.6          12.0     98.1     20.7     96.5     29.3     94.6

  0.46         77.8          68.1          12.4     98.1     21.3     96.5     30.1     94.6

  0.48         73.7          71.7          13.2     97.9     22.4     96.1     31.5     93.9

  0.50         72.4          74.7          14.3     97.9     24.1     96.1     33.6     93.9

  0.52         70.3          75.4          14.3     97.8     24.1     95.8     33.5     93.5

  0.54         68.9          76.0          14.3     97.7     24.2     95.7     33.6     93.3

  0.56         68.5          76.9          14.7     97.7     24.8     95.6     34.4     93.3

  0.58         63.9          79.9          15.6     97.4     26.1     95.2     35.9     92.6

  0.60         61.4          84.6          18.8     97.4     30.7     95.2     41.3     92.5

  0.62         60.4          85.4          19.4     97.4     31.5     95.1     42.2     92.4

  0.64         58.3          86.1          19.6     97.3     31.8     94.9     42.5     92.1

  0.66         56.6          87.6          21.0     97.2     33.7     94.8     44.6     92.0

  0.68         51.5          89.1          21.6     96.9     34.4     94.3     45.5     91.2

  0.70         50.0          90.4          23.3     96.9     36.7     94.2     47.9     91.1

  0.72         47.7          91.4          24.4     96.8     38.1     94.0     49.5     90.8

  0.74         44.6          92.3          25.2     96.6     39.2     93.7     50.5     90.4

  0.76         43.8          92.9          26.4     96.6     40.7     93.7     52.1     90.4

  0.78         41.3          93.8          27.9     96.5     42.5     93.5     54.0     90.1

  0.80         37.1          95.1          30.6     96.3     45.7     93.2     57.2     89.5

  0.82         33.6          95.7          31.3     96.1     46.5     92.8     58.0     89.1

  0.84         30.1          96.4          32.7     96.0     48.2     92.5     59.6     88.7

  0.86         22.4          97.9          38.3     95.6     54.2     91.9     65.3     87.7

  0.88         20.3          98.1          38.3     95.5     54.3     91.7     65.3     87.5

  0.90         14.7          99.6          68.1     95.3     80.3     91.3     86.6     86.9

  0.92         10.4          99.8          75.2     95.0     85.2     90.9     90.2     86.3

  0.94         7.9           100.0         100.0    94.9     100.0    90.7     100.0    86.0

  0.96         3.9           100.0         100.0    94.7     100.0    90.4     100.0    85.5

  0.98         0.6           100.0         100.0    94.5     100.0    90.1     100.0    85.1

  1.00         0.0           100.0         \-       94.5     \-       90.0     \-       85.0
  ----------------------------------------------------------------------------------------------

Prob., probability; PPV, positive predictive value; NPV, negative predictive value

We compared several published predictive models with our current 13-SNP panel (Table [9](#T9){ref-type="table"}). The differences in test performance were evaluated at training and validation stages. The performance of the 13-SNP panel was slightly better than that of the next best test \[[@B41],[@B42]\]. Results from the nine-SNP panel generated from the backwards elimination procedure realised gains in genotyping efficiency, with four fewer variants in the panel, while demonstrating only slightly lower performance in terms of AUC.

###### 

Comparison of models containing different numbers of single nucleotide polymorphisms (SNPs)

  --------------------------------------------------------------------------------------------------------
  Model                              Reported\   Current\    Significance\   Current\      Significance\
                                     AUC         study\      to 13 SNP\      study\        to 13 SNP\
                                                 training\   SCMM\           validation\   SCMM\
                                                 AUC         training        AUC           validation
  ---------------------------------- ----------- ----------- --------------- ------------- ---------------
  **Three-SNP**\                     0.79        0.77        \<0.0001        0.77          \<0.001
  **(Jakobsdottir**\[[@B41]\]**)**                                                         

  **Six-SNP**\                       0.82^a^     0.81        \<0.01          0.79          \<0.05
  **(Seddon**\[[@B42]\]**)**                                                               

  **Nine-SNP**\                      NA          0.81        \<0.01          0.79          ns^b^
  **(SCMM)**                                                                               

  **13-SNP**\                        NA          0.82        \--             0.80          \--
  **(SCMM)**                                                                               
  --------------------------------------------------------------------------------------------------------

AUC, area under the curve; SCMM, Sequenom Center for Molecular Medicine. ^a^AUC value based on model with six SNPs and multiple environmental risk variables (eg baseline grade, education status, BMI, smoking history). ^b^ns: not significant (*p*\> 0.05).

Discussion
==========

Although the incorporation of non-static and self-reported variables is important in elucidating the modifiable risk factors that contribute to disease, their inclusion can degrade test performance in mainstream genetic testing. Ideally, a robust test panel, subject to rigorous validation, which captures the maximal genetic component should improve classification performance and accuracy of reporting. In line with these criteria, which are much stricter than in a discovery cohort, the Boston cohort controls and the Columbia cohort cases and controls were not considered for the calculation of the model. Possible explanations for the allele frequency deviations in these cohorts include admixture, cryptic population stratification, subtle differences in grading criteria, cohort age range, concomitant illnesses or medications, and should be explored further.

In order to compare performance across tests, a ROC curve was generated for each prediction panel to evaluate the AUC. By evaluating each test across the large collective cohort using the same validation procedure, we compared the power of the genetic variants to evaluate classification performance. The performance of the three-SNP panel described by Jakobsdottir and colleagues \[[@B41]\] revealed an AUC value of 0.77, compared with a value of 0.79 observed in the original study of 642 late-stage AMD cases and 142 controls. The differences in AUC values obtained between the original and the current study are likely to reflect the impact of testing across a large collection of independently collected cohorts compared with a single study that is potentially more sensitive to subject selection bias. The performance of the six-SNP test panel reported by Seddon and colleagues \[[@B42]\] as part of a joint gene-environment model exhibited a drop in AUC from 0.81 to 0.79 from training to validation in our data (significant at *P*\< 0.05), similar to most of the tests evaluated. This decrease in AUC reveals the value of the inclusion of an independent validation set to challenge test performance and estimate metrics achievable in the broader clinical setting more accurately. We have emphasised the importance of both study design features to report performance more accurately and to anticipate utility in the more diverse clinical testing market more closely. Finally, modest gains in our 13-SNP panel were demonstrated with the highest AUC value obtained among all models evaluated (0.80). The additional variants that contributed to the performance of the predictive test located in *CFHR5*and F13B highlight the complexity of the genetic structure of the RCA region and influence AMD disease biology.

In summary, the 13-SNP panel had a clinical sensitivity of 82 per cent and a specificity of 63 per cent, achieving clinical performance metrics comparable with models with fewer SNPs that include self-reported and/or non-static risk factors. The PPV of the panel was evaluated at different levels of prevalence, reflecting ranges covering estimates of late-stage disease in individuals \> 40, \> 65 and \> 80 years of age in the general population. More favourable estimates of PPV were observed as the prevalence of disease increases with age. The values obtained revealed 11 per cent PPV at 5.5 per cent prevalence, 20 per cent PPV at 10 per cent prevalence and 28 per cent PPV at 15 per cent prevalence in the general population \[[@B41]\]. The prevalence figures reflect conservative estimates of late-stage disease in the general population and would be further enhanced and more clinically applicable in a setting of diseased patients, as in the study conducted by Seddon and colleagues \[[@B42]\]. The longitudinal study design of the Age-Related Eye Disease Study (AREDS) cohort used in Seddon\'s study was ideal for evaluating incident AMD by distinguishing between \'progressors\' and \'non-progressors\' but, more importantly, it established that the same set of variants were effective at distinguishing non-disease controls from patients with late-stage disease. Not surprisingly, the same core panel of SNPs covering the major genes associated with disease used in Seddon and co-workers\' test panel was also utilised in the study conducted by Jakobsdottir and colleagues,\[[@B41]\] as well as in our current study.

The present confirmatory findings reflect the utility of these variants to predict the development of CNV in non-diseased subjects in our study, as well as the progression to late-stage disease in patients diagnosed with early forms of AMD \[[@B42]\]. PPVs improve significantly when applied to the population of patients diagnosed with early stages of disease. The utility of AMD genetic testing will advance if the result of a predictive test translates into actionable information for the physician. This study highlights the need to continue to explore the biology of CNV, to improve our understanding of the genetics associated with disease and extend these findings in future studies to evaluate clinical performance metrics in the more acute clinical population diagnosed with early-stage disease. A genetic test identifying individuals at high risk of developing CNV holds the promise for earlier detection through risk-based surveillance protocols and improved outcomes arising from more timely intervention.

Supplementary Analysis 1
========================

Logistic regression results
---------------------------

  -----------------------------------------------------------------------
  Model information                                 
  ----------------------------- ------------------- ---------------------
  Dataset                       WORK.SORT8168       

  Response variable             Response            

  Number of response levels     2                   

  Model                         Binary logit        

  Optimisation technique        Fisher\'s scoring   

  Number of observations read   1,000               

  Number of observations used   949                 

                                                    

  **Response profile**\         **Response**        **Total frequency**
  **Ordered value**                                 

                                                    

  1                             0                   467

  2                             1                   482
  -----------------------------------------------------------------------

Probability modelled is response = 0.

Note: 51 observations were deleted due to missing values for the response or explanatory variables.

Backward elimination procedure
------------------------------

###### 

Step 0. The following effects were entered: Intercept rs10490924 rs1061170 rs10922153 rs12144939 rs1409153 rs1750311 rs2230199 rs2274700 rs2990510 rs403846 rs641153 rs698859 rs9332739

  Model convergence status                                                                              
  ------------------------------------------------- -------------------- ------------------------------ -----------------
  Convergence criterion (GCONV = 1E-8) satisfied.                                                       
                                                                                                        
  **Model fit statistics**                                                                              
  **Criterion**                                     **Intercept only**   **Intercept and covariates**   
                                                                                                        
  AIC                                               1317.356             1016.228                       
  SC                                                1322.212             1084.204                       
  -2 Log L                                          1315.356             988.228                        
                                                                                                        
  **Testing global null hypothesis: BETA = 0**                                                          
  **Test**                                          **Chi-square**       **DF**                         **Pr \> ChiSq**
                                                                                                        
  Likelihood ratio                                  327.1278             13                             \<0.0001
  Score                                             280.8660             13                             \<0.0001
  Wald                                              209.1689             13                             \<0.0001

###### 

Step 1. Effect rs698859 is removed:

  Model convergence status                                                                              
  ------------------------------------------------- -------------------- ------------------------------ -----------------
  Convergence criterion (GCONV = 1E-8) satisfied.                                                       
                                                                                                        
  **Model Fit Statistics**                                                                              
  **Criterion**                                     **Intercept only**   **Intercept and covariates**   
                                                                                                        
  AIC                                               1317.356             1014.231                       
  SC                                                1322.212             1077.352                       
  -2 Log L                                          1315.356             988.231                        
                                                                                                        
  **Testing global null hypothesis: BETA = 0**                                                          
  **Test**                                          **Chi-square**       **DF**                         **Pr \> ChiSq**
                                                                                                        
  Likelihood ratio                                  327.1248             12                             \<0.0001
  Score                                             280.8660             12                             \<0.0001
  Wald                                              209.1627             12                             \<0.0001
                                                                                                        
  **Residual Chi-square test**                                                                          
  **Chi-Square**                                    **DF**               **Pr \> ChiSq**                
                                                                                                        
  0.0031                                            1                    0.9559                         

###### 

Step 2. Effect rs1409153 is removed:

  Model convergence status                                                                              
  ------------------------------------------------- -------------------- ------------------------------ -----------------
  Convergence criterion (GCONV = 1E-8) satisfied.                                                       
                                                                                                        
  **Model fit statistics**                                                                              
  **Criterion**                                     **Intercept only**   **Intercept and covariates**   
                                                                                                        
  AIC                                               1317.356             1012.567                       
  SC                                                1322.212             1070.832                       
  -2 Log L                                          1315.356             988.567                        
                                                                                                        
  **Testing global null hypothesis: BETA = 0**                                                          
  **Test**                                          **Chi-square**       **DF**                         **Pr \> ChiSq**
                                                                                                        
  Likelihood ratio                                  326.7893             11                             \<0.0001
  Score                                             280.6633             11                             \<0.0001
  Wald                                              209.0053             11                             \<0.0001
                                                                                                        
  **Residual Chi-square test**                                                                          
  **Chi-square**                                    **DF**               **Pr \> ChiSq**                
                                                                                                        
  0.3389                                            2                    0.8441                         

###### 

Step 3. Effect rs1750311 is removed:

  Model convergence status                                                                              
  ------------------------------------------------- -------------------- ------------------------------ -----------------
  Convergence criterion (GCONV = 1E-8) satisfied.                                                       
                                                                                                        
  **Model fit statistics**                                                                              
  **Criterion**                                     **Intercept only**   **Intercept and covariates**   
                                                                                                        
  AIC                                               1317.356             1010.949                       
  SC                                                1322.212             1064.358                       
  -2 Log L                                          1315.356             988.949                        
                                                                                                        
  **Testing global null hypothesis: BETA = 0**                                                          
  **Test**                                          **Chi-square**       **DF**                         **Pr \> ChiSq**
                                                                                                        
  Likelihood ratio                                  326.4077             10                             \<0.0001
  Score                                             280.4794             10                             \<0.0001
  Wald                                              209.1743             10                             \<0.0001
                                                                                                        
  **Residual Chi-square test**                                                                          
  **Chi-Square**                                    **DF**               **Pr \> ChiSq**                
                                                                                                        
  0.7200                                            3                    0.8685                         

###### 

Step 4. Effect rs12144939 is removed:

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Model convergence status                                                                                                                                                                                                                                          
  ------------------------------------------------------------------------------------------- -------------------- -------------------------------- -------------------- --------------------- ----------------- ----------------- ----------------- -------------- --------------
  Convergence criterion (GCONV = 1E-8) satisfied.                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                                    

  **Model fit statistics**                                                                                                                                                                                                                                          

  **Criterion**                                                                               **Intercept only**   **Intercept and covariates**                                                                                                                     

                                                                                                                                                                                                                                                                    

  AIC                                                                                         1317.356             1010.903                                                                                                                                         

  SC                                                                                          1322.212             1059.457                                                                                                                                         

  -2 Log L                                                                                    1315.356             990.903                                                                                                                                          

                                                                                                                                                                                                                                                                    

  **Testing global null hypothesis: BETA = 0**                                                                                                                                                                                                                      

  **Test**                                                                                    **Chi-square**       **DF**                           **Pr \> ChiSq**                                                                                                 

                                                                                                                                                                                                                                                                    

  **Likelihood ratio**                                                                        324.4536             9                                \<0.0001                                                                                                        

  **Score**                                                                                   279.2738             9                                \<0.0001                                                                                                        

  **Wald**                                                                                    209.2428             9                                \<0.0001                                                                                                        

                                                                                                                                                                                                                                                                    

  **Residual Chi-square test**                                                                                                                                                                                                                                      

  **Chi-square**                                                                              **DF**               **Pr \> ChiSq**                                                                                                                                  

                                                                                                                                                                                                                                                                    

  2.6773                                                                                      4                    0.6132                                                                                                                                           

                                                                                                                                                                                                                                                                    

  Note: No (additional) effects met the 0.05 significance level for removal from the model.                                                                                                                                                                         

                                                                                                                                                                                                                                                                    

  **Summary of backward elimination**                                                                                                                                                                                                                               

  **Step**                                                                                    **Effect removed**   **DF**                           **Number in**        **Wald Chi-square**   **Pr \> ChiSq**                                                      

                                                                                                                                                                                                                                                                    

  1                                                                                           rs698859             1                                12                   0.0031                0.9559                                                               

  2                                                                                           rs1409153            1                                11                   0.3356                0.5624                                                               

  3                                                                                           rs1750311            1                                10                   0.3820                0.5366                                                               

  4                                                                                           rs12144939           1                                9                    1.9468                0.1629                                                               

                                                                                                                                                                                                                                                                    

  **Analysis of maximum likelihood estimates**                                                                                                                                                                                                                      

  **Parameter**                                                                               **DF**               **Estimate**                     **Standard error**   **Wald Chi-square**   **Pr \> ChiSq**                                                      

                                                                                                                                                                                                                                                                    

  Intercept                                                                                   1                    -0.7554                          0.2621               8.3051                0.0040                                                               

  rs10490924                                                                                  1                    -1.4417                          0.1245               134.0342              \<0.0001                                                             

  rs1061170                                                                                   1                    0.7697                           0.2988               6.6352                0.0100                                                               

  rs10922153                                                                                  1                    0.7240                           0.1950               13.7839               0.0002                                                               

  rs2230199                                                                                   1                    -0.4292                          0.1286               11.1389               0.0008                                                               

  rs2274700                                                                                   1                    0.8593                           0.1695               25.7009               \<0.0001                                                             

  rs2990510                                                                                   1                    0.4556                           0.1586               8.2557                0.0041                                                               

  rs403846                                                                                    1                    -0.6775                          0.3341               4.1118                0.0426                                                               

  rs641153                                                                                    1                    0.8243                           0.1999               17.0040               \<0.0001                                                             

  rs9332739                                                                                   1                    0.9509                           0.3163               9.0360                0.0026                                                               

                                                                                                                                                                                                                                                                    

  **Odds ratio estimates**                                                                                                                                                                                                                                          

  **Effect**                                                                                  **Point estimate**   **95% Wald confidence limits**                                                                                                                   

                                                                                                                                                                                                                                                                    

  rs10490924                                                                                  0.237                0.185                            0.302                                                                                                           

  rs1061170                                                                                   2.159                1.202                            3.878                                                                                                           

  rs10922153                                                                                  2.063                1.407                            3.023                                                                                                           

  rs2230199                                                                                   0.651                0.506                            0.838                                                                                                           

  rs2274700                                                                                   2.362                1.694                            3.292                                                                                                           

  rs2990510                                                                                   1.577                1.156                            2.152                                                                                                           

  rs403846                                                                                    0.508                0.264                            0.978                                                                                                           

  rs641153                                                                                    2.280                1.541                            3.374                                                                                                           

  rs9332739                                                                                   2.588                1.392                            4.811                                                                                                           

                                                                                                                                                                                                                                                                    

  **Association of predicted probabilities and observed responses**                                                                                                                                                                                                 

                                                                                                                                                                                                                                                                    

  **Percentage concordant**                                                                   81.5                 **Somers\' D**                   0.637                                                                                                           

  **Percentage discordant**                                                                   17.9                 **Gamma**                        0.641                                                                                                           

  **Percentage tied**                                                                         0.6                  **Tau-a**                        0.319                                                                                                           

  **Pairs**                                                                                   225094               **c**                            0.818                                                                                                           

                                                                                                                                                                                                                                                                    

  **Classification table**                                                                                                                                                                                                                                          

                                                                                              **Correct**          **Incorrect**                                                               **Percentages**                                                      

  **Prob**.\                                                                                  **Event**            **Non-**\                        **Event**            **Non-**\             **Correct**       **Sensitivity**   **Specificity**   **False**\     **False**\
  **Level**                                                                                                        **event**                                             **event**                                                                   **positive**   **negative**

                                                                                                                                                                                                                                                                    

  0.000                                                                                       467                  0                                482                  0                     49.2              100.0             0.0               50.8           \--

  0.020                                                                                       467                  3                                479                  0                     49.5              100.0             0.6               50.6           0.0

  0.040                                                                                       467                  20                               462                  0                     51.3              100.0             4.1               49.7           0.0

  0.060                                                                                       467                  35                               447                  0                     52.9              100.0             7.3               48.9           0.0

  0.080                                                                                       467                  49                               433                  0                     54.4              100.0             10.2              48.1           0.0

  0.100                                                                                       465                  65                               417                  2                     55.8              99.6              13.5              47.3           3.0

  0.120                                                                                       461                  91                               391                  6                     58.2              98.7              18.9              45.9           6.2

  0.140                                                                                       457                  113                              369                  10                    60.1              97.9              23.4              44.7           8.1

  0.160                                                                                       450                  143                              339                  17                    62.5              96.4              29.7              43.0           10.6

  0.180                                                                                       448                  159                              323                  19                    64.0              95.9              33.0              41.9           10.7

  0.200                                                                                       442                  182                              300                  25                    65.8              94.6              37.8              40.4           12.1

  0.220                                                                                       438                  200                              282                  29                    67.2              93.8              41.5              39.2           12.7

  0.240                                                                                       435                  213                              269                  32                    68.3              93.1              44.2              38.2           13.1

  0.260                                                                                       434                  217                              265                  33                    68.6              92.9              45.0              37.9           13.2

  0.280                                                                                       423                  227                              255                  44                    68.5              90.6              47.1              37.6           16.2

  0.300                                                                                       422                  246                              236                  45                    70.4              90.4              51.0              35.9           15.5

  0.320                                                                                       419                  252                              230                  48                    70.7              89.7              52.3              35.4           16.0

  0.340                                                                                       414                  271                              211                  53                    72.2              88.7              56.2              33.8           16.4

  0.360                                                                                       410                  274                              208                  57                    72.1              87.8              56.8              33.7           17.2

  0.380                                                                                       389                  287                              195                  78                    71.2              83.3              59.5              33.4           21.4

  0.400                                                                                       385                  303                              179                  82                    72.5              82.4              62.9              31.7           21.3

  0.420                                                                                       381                  312                              170                  86                    73.0              81.6              64.7              30.9           21.6

  0.440                                                                                       365                  326                              156                  102                   72.8              78.2              67.6              29.9           23.8

  0.460                                                                                       361                  331                              151                  106                   72.9              77.3              68.7              29.5           24.3

  0.480                                                                                       358                  340                              142                  109                   73.6              76.7              70.5              28.4           24.3

  0.500                                                                                       344                  354                              128                  123                   73.6              73.7              73.4              27.1           25.8

  0.520                                                                                       332                  357                              125                  135                   72.6              71.1              74.1              27.4           27.4

  0.540                                                                                       324                  366                              116                  143                   72.7              69.4              75.9              26.4           28.1

  0.560                                                                                       315                  378                              104                  152                   73.0              67.5              78.4              24.8           28.7

  0.580                                                                                       300                  389                              93                   167                   72.6              64.2              80.7              23.7           30.0

  0.600                                                                                       293                  392                              90                   174                   72.2              62.7              81.3              23.5           30.7

  0.620                                                                                       284                  398                              84                   183                   71.9              60.8              82.6              22.8           31.5

  0.640                                                                                       266                  410                              72                   201                   71.2              57.0              85.1              21.3           32.9

  0.660                                                                                       252                  417                              65                   215                   70.5              54.0              86.5              20.5           34.0

  0.680                                                                                       236                  423                              59                   231                   69.4              50.5              87.8              20.0           35.3

  0.700                                                                                       233                  427                              55                   234                   69.5              49.9              88.6              19.1           35.4

  0.720                                                                                       196                  440                              42                   271                   67.0              42.0              91.3              17.6           38.1

  0.740                                                                                       190                  441                              41                   277                   66.5              40.7              91.5              17.7           38.6

  0.760                                                                                       179                  448                              34                   288                   66.1              38.3              92.9              16.0           39.1

  0.780                                                                                       170                  453                              29                   297                   65.6              36.4              94.0              14.6           39.6

  0.800                                                                                       127                  456                              26                   340                   61.4              27.2              94.6              17.0           42.7

  0.820                                                                                       114                  467                              15                   353                   61.2              24.4              96.9              11.6           43.0

  0.840                                                                                       103                  467                              15                   364                   60.1              22.1              96.9              12.7           43.8

  0.860                                                                                       77                   470                              12                   390                   57.6              16.5              97.5              13.5           45.3

  0.880                                                                                       65                   471                              11                   402                   56.5              13.9              97.7              14.5           46.0

  0.900                                                                                       53                   475                              7                    414                   55.6              11.3              98.5              11.7           46.6

  0.920                                                                                       40                   479                              3                    427                   54.7              8.6               99.4              7.0            47.1

  0.940                                                                                       16                   481                              1                    451                   52.4              3.4               99.8              5.9            48.4

  0.960                                                                                       9                    481                              1                    458                   51.6              1.9               99.8              10.0           48.8

  0.980                                                                                       1                    481                              1                    466                   50.8              0.2               99.8              50.0           49.2

  1.000                                                                                       0                    482                              0                    467                   50.8              0.0               100.0             \--            49.2
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